^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CMV/CD19 bi-Specific CAR T

    i
    Other names: CMV/CD19 bi-Specific CAR T, CMV-specific CD19-CAR T Cells, anti-CD19-CAR CMV-specific T-cells, Anti-CD19-CAR CMV-specific T-lymphocytes
    Associations

    News

    Trials
    Company:
    City of Hope
    Drug class:
    CD19-targeted CAR-T immunotherapy, CMV-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    9ms
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2026 --> Dec 2028 | Trial primary completion date: Sep 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Triplex vaccine
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    9ms
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2027 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over1year
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Triplex vaccine
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over1year
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy • Triplex vaccine
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    2years
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over2years
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    over2years
    Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor) • CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    cytarabine • carmustine • melphalan • CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)